Tirzepatide Heart Rate and Palpitations: What Trial Numbers Mean

Tirzepatide can raise average heart rate modestly. That finding does not tell you the cause of a new pounding, racing or irregular heartbeat. A pulse measurement, the sensation of palpitations and a diagnosed arrhythmia describe different things. New or recurring symptoms deserve an assessment even when a study reports a small average change.¹²

Call emergency services for palpitations with chest pain, severe shortness of breath, fainting or collapse. A reassuring smartwatch reading should not delay help when serious symptoms are present.³

What the measured changes actually were

The current Zepbound prescribing information reports a mean increase of 1–3 beats per minute in pooled weight-management trials, compared with no increase in placebo-treated patients.¹ An average is not an upper limit; it does not mean that every person changes by exactly that amount.

A separate SURMOUNT-1 substudy used 24-hour ambulatory monitoring. At week 36, the heart-rate increases relative to placebo were 2.1, 2.3 and 5.4 beats per minute for tirzepatide 5, 10 and 15 mg, respectively. The baseline average was 77.4 beats per minute. These are adjusted between-group differences from a defined research setting, not thresholds for deciding whether a symptom is safe.⁴

The substudy enrolled 600 people; 494 had valid ambulatory blood-pressure data at both baseline and week 36. Participants did not have type 2 diabetes and entered with blood pressure below 140/90 mm Hg. Those details limit how confidently the results can be applied to someone with a different medical history.⁴

Why the numbers differ between reports

A clinic pulse and a 24-hour average are different measurements. So are a change from a person's own baseline and a change after subtracting the placebo group's change. The treatment duration also matters. Reading these numbers side by side is helpful only when the measurement method and time point remain attached.

For personal tracking, a sequence of readings collected under similar conditions is easier to interpret than comparing a post-exercise reading with one taken while resting. Tell the clinician what you were doing, whether symptoms were present and whether the device reported an irregular rhythm. The record supports an evaluation; it does not replace one.

Palpitations are a symptom, not an arrhythmia diagnosis

People use “palpitations” to mean fluttering, skipped beats, pounding or racing. Some rhythm problems cause symptoms, while others do not. NHLBI describes diagnosis using the history, an examination, an electrocardiogram and sometimes longer monitoring to capture episodes that are not present during the appointment.²⁵

This distinction helps avoid two opposite mistakes. A sensation is not proof that tirzepatide caused a dangerous rhythm. But a normal pulse at a later moment does not prove the earlier episode was harmless. If symptoms come and go, write down their duration and frequency and discuss whether monitoring is appropriate.

A wearable may provide a useful time-stamped record to share. It cannot determine every cause of a racing heart or rule out all cardiac conditions. Keep the device data alongside the symptoms rather than treating one green check mark as the final answer.

Other treatment changes may belong in the history

Tell the clinician about vomiting, diarrhea, reduced intake, recent illness, new supplements and changes in caffeine or other medicines. These details help build a differential diagnosis rather than assume the newest prescription is the whole explanation.

For people using insulin or a sulfonylurea, a rapid heartbeat may accompany low glucose. Our hypoglycemia article explains why the background diabetes regimen matters. Follow your existing glucose-check plan if symptoms suggest a low; do not diagnose the cause from heart rate alone.⁶

If you have an established arrhythmia, bring the name of the rhythm diagnosis and the medicines used to treat it. “Heart trouble” is less useful than knowing whether a prior test showed atrial fibrillation, another rhythm, or no abnormality. A prescriber may need records from the cardiology team before interpreting a new symptom.

Does a higher pulse cancel a cardiovascular benefit?

Neither pulse nor body weight alone can answer that question. A cardiovascular-outcomes study asks whether events such as hospitalization or cardiovascular death differ between treatment groups. A heart-rate analysis measures a physiological variable. A favorable result for one cannot be substituted for the other.

The SUMMIT randomized trial studied people with obesity and heart failure with preserved ejection fraction, a specific clinical population. It found a benefit for its composite cardiovascular-death or worsening-heart-failure outcome. That finding should not be turned into a claim that tirzepatide treats every arrhythmia or protects every patient from palpitations.⁷

The HFpEF evidence guide covers that trial's population and outcomes. The blood-pressure guide addresses another related measurement. Keeping these questions separate makes the evidence more useful, not less reassuring.

What to bring to an appointment

A brief symptom record is often more helpful than a long list of isolated readings:

• •When the episode started and how long it lasted.
• •Whether the heartbeat felt fast, irregular, forceful or like a skipped beat.
• •Whether you were resting, standing, eating or exercising.
• •Any dizziness, breathlessness, chest discomfort or faintness.
• •Your most recent injection date and prescribed dose.
• •Other medicines, supplements and relevant glucose readings.

Ask whether you need an ECG, longer monitoring or a review of other possible contributors. Also ask what to do if symptoms recur outside office hours and whether the next scheduled dose needs to wait for assessment. Do not self-treat with someone else's heart medication or change a prescribed cardiac medicine based on a general article.

How we interpret the evidence

The small average pulse increase is a reproducible trial observation. It is not a patient-specific diagnosis, a “safe racing-heart” allowance or a way to rule out an arrhythmia. The most useful next step for recurring palpitations is to connect the symptom timeline with an appropriate clinical evaluation.

This article was researched in October 2026 using the current product label, the ambulatory monitoring substudy and primary trial evidence.